Engineering DNA for next-generation therapeutics and forensics

At Parabon NanoLabs, we are developing a new class of nano-pharmaceuticals and advanced forensic tools by fully leveraging the power of DNA.


> Who We Are

> What We Do

> Our Technologies

Whether chemically engineering synthetic DNA for creating nano-pharmaceuticals or reverse engineering human DNA for biomarkers of medical or forensic significance, Parabon NanoLabs is developing some of the most compelling products of the DNA Age.

For example, our scientists and customers use the Parabon Essemblix™ Drug Development Platform to design and produce potent new compounds for the treatment of cancer, infectious disease and biodefense applications.

We are also developing the Parabon Snapshot™ DNA Phenotyping System, which produces a descriptive profile of the source of any human DNA sample, including pigmentation, face morphology and other forensically relevant traits.


To learn more about our products and services, check out the Therapeutics and Forensics pages.

Latest News

5 Private Biotechs Revolutionizing MedicineFool.com

Maxx Chatsko, writing for The Motley Fool

Parabon NanoLabs to be showcased at 12th Annual BIO Investor Forum

Join us October 8-9th at the Palace Hotel in San Francisco, CA #BIF13

Parabon NanoLabs: Applied DNA Nanotechnology, from Custom-Designed Drugs to Virtual Mug Shots

Parabon NanoLabs profiled by Duke University Department of Electrical & Computer Science

Parabon Awarded CRCF Grant for
Artificial Vaccine Platform

CIT Announces Awards for the Commonwealth Research Commercialization Fund (CRCF) FY2013 Solicication

Biotechs Explore Role for 3D Printing
In Drug Development

Parabon Nanolabs profiled by New York Genome Center (nygenome.org)

The 7 Best Inventions of 2012

Huffington Post names Parabon Essemblix one of the seven best inventions of 2012

Parabon NanoLabs Awarded NSF Grant for Development of Cancer Therapeutic with Industry Partner Janssen R&D

Novel formulation aims to reduce side-effects and improve efficacy of approved chemotherapeutic compound

More news